How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Authors
Keywords
Antiviral treatment, entecavir, tenofovir, nucleos(t)ide analogue, Antiviral, cccDNA, hepatitis B surface antigen clearance, Immune modulation
Journal
JOURNAL OF HEPATOLOGY
Volume 76, Issue 6, Pages 1249-1262
Publisher
Elsevier BV
Online
2022-05-16
DOI
10.1016/j.jhep.2021.11.024
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection
- (2021) Akira Nishio et al. Science Translational Medicine
- Endpoints and New Options for Treatment of Chronic Hepatitis D
- (2021) Anna S. Lok et al. HEPATOLOGY
- APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients
- (2021) Jia-Horng Kao et al. Hepatology International
- Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections
- (2021) Maria Guadalupe Martinez et al. JOURNAL OF HEPATOLOGY
- Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial
- (2021) Man-Fung Yuen et al. Lancet Gastroenterology & Hepatology
- Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy
- (2020) Michel Bazinet et al. GASTROENTEROLOGY
- Should treatment indications for chronic hepatitis B be expanded?
- (2020) Wen-Juei Jeng et al. Clinical Gastroenterology and Hepatology
- JNJ-56136379, an HBV Capsid Assembly Modulator, is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection
- (2020) Fabien Zoulim et al. GASTROENTEROLOGY
- Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study
- (2020) Minseok Albert Kim et al. GUT
- Rapid Turnover of HBV cccDNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients
- (2020) Qi Huang et al. HEPATOLOGY
- Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B
- (2020) Emilia Hadziyannis et al. Expert Review of Gastroenterology & Hepatology
- Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro
- (2020) Richard Boulon et al. ANTIVIRAL RESEARCH
- Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with isis 505358 in chronic hepatitis B (CHB) patients on stable nucleos (t)ide analogue (NA) regimen and in NA-naive CHB patients: phase 2a, randomized, double-blind, placebo-controlled study
- (2020) Man-Fung Yuen et al. JOURNAL OF HEPATOLOGY
- Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study
- (2020) Man-Fung Yuen et al. JOURNAL OF HEPATOLOGY
- Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients
- (2020) Edward Gane et al. JOURNAL OF HEPATOLOGY
- Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial
- (2020) Florian van Bömmel et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data
- (2020) Harry Janssen et al. JOURNAL OF HEPATOLOGY
- Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients
- (2020) Mireia García-López et al. JOURNAL OF HEPATOLOGY
- Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection
- (2019) Man Fung Yuen et al. GASTROENTEROLOGY
- Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load
- (2019) Anita Schuch et al. GUT
- Combined GS-4774 and Tenofovir Therapy can Improve HBV-Specific T-Cell Responses in Patients with Chronic Hepatitis
- (2019) Carolina Boni et al. GASTROENTEROLOGY
- GS-12-Ascending dose cohort study of inarigivir - A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial
- (2019) Man-Fung Yuen et al. JOURNAL OF HEPATOLOGY
- Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
- (2019) Patrick Marcellin et al. LIVER INTERNATIONAL
- HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications
- (2019) Carolina Boni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study
- (2019) Edward Gane et al. JOURNAL OF HEPATOLOGY
- Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B
- (2019) Hong Ren et al. JOURNAL OF VIRAL HEPATITIS
- Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)
- (2019) Kin Seng Liem et al. GUT
- Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
- (2019) Man-Fung Yuen et al. Lancet Gastroenterology & Hepatology
- The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg‐negative chronic hepatitis B
- (2019) Grace L.‐H. Wong et al. LIVER INTERNATIONAL
- TLR7 Agonist Increases Responses of Hepatitis B Virus–Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues
- (2018) Carolina Boni et al. GASTROENTEROLOGY
- Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B
- (2018) Wen-Juei Jeng et al. HEPATOLOGY
- Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation
- (2018) Laura Rivino et al. JOURNAL OF CLINICAL INVESTIGATION
- First clinical evaluation in chronic hepatitis B patients of the synthetic farnesoid X receptor agonist EYP001
- (2018) R. Erken et al. JOURNAL OF HEPATOLOGY
- Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B
- (2018) Harry L.A. Janssen et al. JOURNAL OF HEPATOLOGY
- Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients
- (2018) Terry Cheuk-Fung Yip et al. JOURNAL OF HEPATOLOGY
- Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B
- (2018) Franziska Rinker et al. JOURNAL OF HEPATOLOGY
- Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection
- (2018) Gian Paolo Caviglia et al. JOURNAL OF HEPATOLOGY
- Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA?
- (2018) Markus Cornberg et al. Nature Reviews Gastroenterology & Hepatology
- Circulating and intrahepatic antiviral B cells are defective in hepatitis B
- (2018) Alice R. Burton et al. JOURNAL OF CLINICAL INVESTIGATION
- HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues
- (2018) Terry Cheuk-Fung Yip et al. JOURNAL OF HEPATOLOGY
- Antiviral activity of GS-5801, a liver-targeted prodrug of a lysine demethylase 5 inhibitor, in a hepatitis B virus primary human hepatocyte infection model
- (2017) S. Gilmore et al. JOURNAL OF HEPATOLOGY
- Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B
- (2017) Fanny Lebossé et al. JOURNAL OF HEPATOLOGY
- The role of quantitative hepatitis B surface antigen revisited
- (2017) Markus Cornberg et al. JOURNAL OF HEPATOLOGY
- Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study
- (2017) Thomas Berg et al. JOURNAL OF HEPATOLOGY
- Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B
- (2017) Paola Fisicaro et al. NATURE MEDICINE
- RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg
- (2017) Christine I. Wooddell et al. Science Translational Medicine
- Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients
- (2017) C.-H. Chen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
- (2016) Patrick Marcellin et al. GASTROENTEROLOGY
- Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients
- (2016) Anders Boyd et al. JOURNAL OF HEPATOLOGY
- Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B
- (2016) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- Adaptive immunity in HBV infection
- (2016) Antonio Bertoletti et al. JOURNAL OF HEPATOLOGY
- Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection
- (2016) Mamun Al-Mahtab et al. PLoS One
- Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient
- (2015) Waseem Qasim et al. JOURNAL OF HEPATOLOGY
- Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013
- (2015) Aparna Schweitzer et al. LANCET
- Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck
- (2014) Anna D. Kosinska et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY
- Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA
- (2014) J. Lucifora et al. SCIENCE
- GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees
- (2013) Robert E. Lanford et al. GASTROENTEROLOGY
- HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
- (2013) Gi-Ae Kim et al. GUT
- Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir
- (2012) Stephanos J. Hadziyannis et al. GASTROENTEROLOGY
- Altered Functions of Plasmacytoid Dendritic Cells and Reduced Cytolytic Activity of Natural Killer Cells in Patients With Chronic HBV Infection
- (2012) Jeremie Martinet et al. GASTROENTEROLOGY
- Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues
- (2012) Carolina Boni et al. GASTROENTEROLOGY
- Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
- (2010) A. M. Evens et al. ANNALS OF ONCOLOGY
- Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection
- (2008) Abhishek Das et al. JOURNAL OF EXPERIMENTAL MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started